First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma

Although the availability of effective novel treatments has positively impacted the quality of life and survival of newly diagnosed multiple myeloma (MM) patients, benefits in the transplant ineligible MM (TIMM) population may be limited by functional/frailty status.The Canadian Myeloma Research Group Consensus Guideline Consortium (CMRG-CGC) proposes consensus recommendations for the first-line treatment of TIMM. To address the needs of physicians and people diagnosed with MM, this document further focuses on eligibility for transplant, frailty assessment, management of adverse events, assessment of treatment response, and monitoring for disease relapse.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research